ZUG, Switzerland, November 21, 2023 Galderma: Galderma achieved net sales of 3,009 M USD over the first nine months of 2023, up 8.9% year-on-year on a constant currency basisContinued pipeline progress with new milestones reached for nemolizumab and RelabotulinumtoxinAGalderma is on track to deliver at the upper end of its 2023 net sales guidance of 6-9% constant currency growth, and is in line with its profitability guidance of 200-300 bps core EBITDA margin expansion versus 2022"We are very p
Galderma, the emerging pure-play dermatology category leader, announced today updates related to the regulatory progress of its pending Biologics License Application ("BLA") for RelabotulinumtoxinA (QM-1114) to the U.S. Food and Drug Administration.